C.R. Bard (NYSE: BCR) reported earnings on April 24. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), C.R. Bard met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share expanded.

Gross margins contracted, operating margins contracted, net margins grew.

Revenue details
C.R. Bard logged revenue of $730.0 million. The 14 analysts polled by S&P Capital IQ anticipated a top line of $732.7 million on the same basis. GAAP reported sales were 4.2% higher than the prior-year quarter's $700.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $1.61. The 19 earnings estimates compiled by S&P Capital IQ forecast $1.57 per share on the same basis. GAAP EPS of $1.60 for Q1 were 7.4% higher than the prior-year quarter's $1.49 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 61.7%, 50 basis points worse than the prior-year quarter. Operating margin was 27.4%, 20 basis points worse than the prior-year quarter. Net margin was 19.0%, 20 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $757.6 million. On the bottom line, the average EPS estimate is $1.65.

Next year's average estimate for revenue is $3.03 billion. The average EPS estimate is $6.66.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 263 members out of 275 rating the stock outperform, and 12 members rating it underperform. Among 95 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 92 give C.R. Bard a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on C.R. Bard is hold, with an average price target of $93.36.

The healthcare investing landscape is littered with also-rans and a few major winners. Is C.R. Bard the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.